....I have been thinking for a while that one potential scenario might be that Zenith is working on a deal for Zen-3694. The upfront money from a sale would probably be enough for ZCC to then invest that money in RVX and see BetOnMace through to the end as well as fund at least the CKD work if not more....

I see about a .001% chance of that happening.  Anyhow, I'd be strongly opposed to it.  Zenith separated into two companies for a reason.  The RVX risk/reward is with Zenith Capital Corp.  It would make no sense for the operational splitoff (Zenith Epigenetics) to now dive back into RVX.

Cash from any deals with Zenith Epigenetics Ltd should be put into the next studies and toward an IPO on the Nasdaq (as is currently in their plans).